Name: Ravidasvir Hydrochloride Tablets 200?mg Low price comparison - Arizona-mall
Price: 1.00 HKD
Availability: InStock

Ravidasvir Hydrochloride Tablets 200?mg Low price comparison

$1.00

Xinlilai (Ascletis) Ravidasvir Hydrochloride Tablets deliver 200?mg per tablet, 14 tablets per bottle. Manufactured by Ascletis Pharma, approved under NMPA H20200008. Investigated as an NS5A inhibitor in Hepatitis C virus (HCV) research.
?? For research use only. Not intended for human or veterinary treatment.?Please consult staff for other specifications and uses?

Compare

描述

Ravidasvir Hydrochloride is a novel NS5A inhibitor under study for its antiviral effects against Hepatitis C Virus (HCV). It is primarily investigated in combination with other agents such as sofosbuvir for pan-genotypic antiviral research. This product is provided in tablet form for experimental modeling of HCV replication, resistance profiling, and antiviral screening.

Manufactured by Ascletis Pharma (Zhejiang) Co., Ltd., this formulation is regulated under NMPA approval number H20200008. The compound shows promise in studies targeting genotype 1-6 HCV RNA.

Contents hide

1 Product Specifications

2 Mechanism of Action

3 Research Applications

4 Safety & Handling

5 Core Keywords

6 Research Use Disclaimer

Product Specifications

Parameter	Details
Product Name	Ravidasvir Hydrochloride Tablets (Xinlilai / Ascletis)
Generic Name	Ravidasvir Hydrochloride
CAS Number	1448757-44-1
Molecular Formula	C??H??ClN?O?
Molecular Weight	~758.3?g/mol
Dosage Form	Oral tablets
Strength	200 mg per tablet
Quantity	14 tablets per bottle
Approval No.	H20200008
Drug Code	86981008000028
Manufacturer	Ascletis Pharma (Zhejiang) Co., Ltd.
Barcode	6973125730005
Storage Conditions	Store below 25?°C, dry and sealed
Intended Use	Laboratory use in antiviral and HCV research only

Mechanism of Action

Ravidasvir Hydrochloride is a potent NS5A replication complex inhibitor. It disrupts the replication and assembly of HCV RNA by targeting the NS5A protein domain, making it a key candidate in pan-genotypic antiviral research, especially in combination with sofosbuvir.

Research Applications

Hepatitis C Virus (HCV) inhibition modeling
Resistance testing in NS5A mutant strains
Antiviral pharmacokinetics and in vitro potency studies
Combination therapy research with DAAs (Direct-Acting Antivirals)
Liver cell line HCV propagation and clearance studies

Safety & Handling

Use only in approved laboratory facilities
Use standard protective equipment (gloves, goggles, coat)
Not for ingestion, inhalation, or injection
Dispose in accordance with lab waste guidelines
Not for human clinical or diagnostic use

Core Keywords

ravidasvir hydrochloride tablets, ravidasvir CAS 1448757-44-1, Xinlilai Ascletis tablets, NS5A inhibitor research, HCV antiviral compound, wholesale ravidasvir tablets, H20200008, experimental hepatitis C drug

Research Use Disclaimer

This product is provided exclusively for scientific research and laboratory applications. It is not approved for therapeutic, clinical, or diagnostic use in humans or animals. Misuse may carry regulatory and health risks. Use under institutional protocols only.

其他信息

重量	1 公斤
尺寸	26 × 23 × 26 厘米

评价

目前还没有评价

成为第一个“Ravidasvir Hydrochloride Tablets 200?mg Low price comparison” 的评价者

Q1: What is the CAS number of Ravidasvir Hydrochloride?

A1: CAS 1448757-44-1, confirming its structure and identity.

Q2: Is this for therapeutic use?

A2: No. This product is intended only for research use in laboratories and institutions.

Q3: Can I order in bulk?

A3: Yes, both bulk and retail orders are supported with international shipping.

Q4: Do you provide documentation?

A4: Yes, we can provide COA (Certificate of Analysis) and SDS (Safety Data Sheet) upon request.

Q5: Is it used alone or in combination?

A5: In research, it is often studied in combination with sofosbuvir for enhanced antiviral effect.

Q6: What genotypes is it active against?

A6: It has demonstrated pan-genotypic (genotypes 1-6) activity in HCV replication models.